Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.

Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.

In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.

Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.

The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).

New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.

Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.